基于细胞外囊泡来源lncRNA的液体活检特征对早发性胃癌早期检测的诊断效能
本研究通过分析早发性胃癌(EOGC)、晚发性胃癌(LOGC)及年龄匹配非疾病对照的组织转录组数据,并在训练队列(n=299)血液样本中鉴定细胞外囊泡来源长非编码RNA(EV-lncRNA)特征,随后在两个外部验证队列(n=462和n=438)、术前/术后队列(n=66)及胃肠道肿瘤队列(n=225)中用qPCR确认。开发出由NALT1、PTENP1和HOTTIP组成的三EV-lncRNA液体活检特征,用于EOGC检测的AUROC为0.924(95% CI 0.889至0.953),在两个外部验证队列中分别显示AUROC 0.911(西安队列)和0.9323(北京队列)。
要点
- 三EV-lncRNA特征(NALT1、PTENP1、HOTTIP)检测EOGC的AUROC为0.924(95% CI 0.889至0.953)。
- 外部验证队列中西安队列AUROC为0.911,北京队列AUROC为0.9323。
- 该特征可识别可切除期(I/II期)EOGC,且区分I期EOGC与癌前病变的性能优于传统胃癌相关生物标志物。
核心结论
- 新开发的EV-lncRNA特征能有效识别可切除期的EOGC患者,精度提高,从而改善原本可能错过治愈窗口的患者的预后。
研究设计与样本
- 系统发现方法:分析EOGC(n=43)、LOGC(n=31)和年龄匹配非疾病对照(n=37)组织样本的全基因组转录组谱数据。
- 在训练队列(n=299)血液样本中鉴定EV-lncRNA特征,并在两个外部验证队列(n=462和n=438)、术前/术后队列(n=66)及胃肠道肿瘤队列(n=225)中用qPCR确认。
主要发现
- 开发出由NALT1、PTENP1和HOTTIP组成的三EV-lncRNA液体活检特征,用于EOGC检测的AUROC为0.924(95% CI 0.889至0.953)。
- 该EV-lncRNA特征在两个外部验证队列中提供稳健的诊断性能:西安队列AUROC为0.911,北京队列AUROC为0.9323。
- 该EV-lncRNA特征可靠地识别可切除期(I/II期)EOGC患者,并在区分早期(I期)EOGC与癌前病变方面表现出优于传统胃癌相关生物标志物的诊断性能。
- 术后和其他胃肠道肿瘤血浆样本中该生物标志物水平低,表明其对胃癌具有特异性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-onset gastric cancer (EOGC) is a lethal malignancy. It differs from late-onset gastric cancer (LOGC) in clinical and molecular characteristics. The current strategies for EOGC detection have certain limitations in diagnostic performance due to the rising trend in EOGC. OBJECTIVE: We developed a liquid biopsy signature for EOGC detection. DESIGN: We use a systematic discovery approach by analysing genome-wide transcriptomic profiling data from EOGC (n=43), LOGC (n=31) and age-matched non-disease controls (n=37) tissue samples. An extracellular vesicle-derived long non-coding RNA (EV-lncRNA) signature was identified in blood samples from a training cohort (n=299), and subsequently confirmed by qPCR in two external validation cohorts (n=462 and n=438), a preoperative/postoperative cohort (n=66) and a gastrointestinal tumour cohort (n=225). RESULTS: A three EV-lncRNA (NALT1, PTENP1 and HOTTIP) liquid biopsy signature was developed for EOGC detection with an area under the receiver operating characteristic curve (AUROC) of 0.924 (95% CI 0.889 to 0.953). This EV-lncRNA signature provided robust diagnostic performance in two external validation cohorts (Xi'an cohort: AUROC, 0.911; Beijing cohort: AUROC, 0.9323). Furthermore, the EV-lncRNA signature reliably identified resectable stage EOGC patients (stage I/II) and demonstrated better diagnostic performance than traditional GC-related biomarkers in distinguishing early-stage EOGC (stage I) from precancerous lesions. The low levels of this biomarker in postsurgery and other gastrointestinal tumour plasma samples indicated its GC specificity. CONCLUSIONS: The newly developed EV-lncRNA signature effectively identified EOGC patients at a resectable stage with enhanced precision, thereby improving the prognosis of patients who would have otherwise missed the curative treatment window.
引用
- Guo X, Wang W, Cheng X, et al. Diagnostic efficacy of an extracellular vesicle-derived lncRNA-based liquid biopsy signature for the early detection of early-onset gastric cancer. Gut. 2025. PMID: 40113244. doi:10.1136/gutjnl-2024-333657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。